ANZICS CTG Endorsed Study
The effect of augmented administration of enteral protein to critically ill adults on clinical outcomes: A cluster randomised, cross-sectional double cross-over, registry-embedded, pragmatic clinical trial.
The TARGET Protein study is a cluster randomised clinical trial with the aim of evaluating the effect of isocaloric higher dietary protein delivery on outcomes of critically ill adult patients when compared to usual care. In this study each ICU will be randomised to one of the two study formulae for 3 months and then crosses over to the other study formulae for 3 months, which is then repeated, with each site participating for 12 months. Each eligible patient admitted to the ICU during these 3-month periods will receive the same study formula.
Rinaldo Bellomo, Marianne Chapman, Lee-anne Chapple, Adam Deane, Suzie Ferrie, Mark Finnis, Criag French, Sally Hurford, Nima Kakho, Emily Karahalios, Matthew Maiden, Stephanie O’Connor, Sandra Peake, Jeffrey Presneill, Emma Ridley, Matthew Summers, An Duy Tran, Tricia Williams, Paul Young
Royal Adelaide Hospital, Central Adelaide Local Health Network
Intensive Care Foundation, MRFF, Nutricia Australia
CTG 2122-03, ACTRN12621001484831
Adam Deane (email)
Lee-anne chapple (email)